Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


ESMO 2018 in depth: Resistance mechanisms to osimertinib in patients with NSCLC and a EGFR T790M mutation

Vassiliki Papadimitrakopoulou, MD, oncologist at the MD Anderson Cancer Centre in Texas, provides information on EGFR mutations associated with resistance to osimertinib in patients with NSCLC and a T790M mutation. These results are from an analysis of the AURA3 study.

  • Invited speakers

  • Vassiliki Papadimitrakopoulou, MD

    medical oncologist

    MD Anderson Cancer Centre, Texas, USA

  • Sponsors

    This program is editorially independent and is financially made possible by

Related items

Congresnieuws 06/11/2018

ESMO 2018 in depth: IMpower 130

Federico Cappuzzo, MD, oncologist at AUSL Romagna in Ravenna, provides information on the IMpower130. A study of carboplatin + nab-paclitaxel with or without atezolizumab as first-line therapy in advanced NSCLC.   

Congresnieuws 06/11/2018

ESMO 2018 in depth: Checkmate 142

Heinz-Josef Lenz, MD, oncologist at USC, Norris Comprehensive Cancer Center in Los Angeles provides information on the Checkmate 142. A study of nivolumab plus ipilimumab as first-line therapy in MSI-H/dMMR metastatic colorectal cancer. 

Congresnieuws 22/03/2018

ESMO 2017 in-depth: Neoadjuvant chemotherapy in cervical cancer

This year the ESMO congress took place in Madrid from 8 - 12 September. Sudeep Gupta, Professor of Medical Oncology at Tata Memorial Hospital in Mumbai, explains the design and results of his trial, that examined whether neoadjuvant chemotherapy followed by surgical removal of the tumour could improve outcomes in patients with locally advanced cervical cancer compared to standard treatment with chemoradiation.

Congresnieuws 22/03/2018

ESMO 2017 in-depth: TONIC trial

This year the ESMO congress took place in Madrid from 8 - 12 September. Marleen Kok, MD, PhD at The Netherlands Cancer Institute in Amsterdam, explains the design and first results of the TONIC trial. This adaptive phase II trial evaluated the response rate to nivolumab after induction treatment in patients with triple-negative breast cancer.

Congresnieuws 12/09/2017

ESMO 2017 in-depth: KEYNOTE-040 trial

This year the ESMO congress took place in Madrid from 8 - 12 September. E. This phase III trial evaluated the efficacy of checkpoint inhibitor pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma after platinum-based chemotherapy.

Congresnieuws 12/09/2017

ESMO 2017 in-depth: RANGE trial

This year the ESMO congress took place in Madrid from 8 - 12 September. Daniel Petrylak, Professor of Medicine and Urology at Yale School of Medicine, explains the design and results of the RANGE trial. This phase III randomised trial evaluated the efficacy of ramucirumab in combination with docetaxel in patients with advanced urothelial cancer who failed prior platinum-based therapy.